Loading…
This entity appears on both sides of lobbying disclosures. The firm tab shows registrant-reported income; the client tab shows client-reported lobbying spend. Contract awards are separate and are not included here.
Lobbying Spend
$1.8M
Filings
37
Firms Hired
2
Active Period
2018–2024
Client-reported lobbying expenses on LDA filings
Lobbying firms retained by this client; amounts are client-reported expenses when available
Government entities explicitly identified as targets in LDA filings
Most frequently reported lobbying issues
Bill numbers found in source-reported LDA specific issue text; broad topic matches are excluded
Medicaid VBPs for Patients Act
2023 · fourth_quarter · Firm: KNIGHT CAPITOL CONSULTANTS
Potential amendments to the Social Security Act to allow value-based pricing under Medicaid (HR 2666)
Client expense: — · Firm income: $50,000
Matched citations: HR 2666
Medicaid VBPs for Patients Act
2023 · fourth_quarter · Firm: KNIGHT CAPITOL CONSULTANTS
Issues affecting biotechnology firms engaged in developing gene therapies, including: the MVP Act (H.R.2666) authorizing value based payments under the Medicaid program; Proposals to amend the drug pricing provisions of the Inflation Reduction Act such as reducing the 13-year period before newly approved biologics are subject to negotiated prices; Changes to the Orphan Drug Act; and, Potential legislative or administrative changes to the FDA accelerated approval program including reimbursement of AAP-approved gene therapies (e.g., MedPAC recommendations to cap prices for FDAcAAP-approved products under certain circumstances.) Potential amendments to the Food, Drug and Cosmetic Act, the Public Health Service Act, or the Social Security Act that would impact the provision of cell and gene therapies (no specific legislation):. -
Client expense: — · Firm income: $50,000
Matched citations: H.R.2666
Issues affecting biotechnology firms engaged in developing gene therapies, including: the MVP Act (H.R.2666) authorizing value based payments under the Medicaid program; Proposals to amend the drug pricing provisions of the Inflation Reduction Act such as reducing the 13-year period before newly approved biologics are subject to negotiated prices; Changes to the Orphan Drug Act; and, Potential legislative or administrative changes to the FDA accelerated approval program including reimbursement of AAP-approved gene therapies (e.g., MedPAC recommendations to cap prices for FDA AAP-approved products under certain circumstances.) Efforts to enact a so-called "reasonable pricing clause" in NIH licenses and CRADAs
Client expense: $91,000 · Firm income: —
Matched citations: H.R.2666
Proposals to allow the direct expensing of R&D expenditures, including S.866, the American Innovation and Jobs Act (S.866) and the Build It in America Act (H.R. 3938).
Client expense: $91,000 · Firm income: —
Matched citations: H.R. 3938
Patent Eligibility Restoration Act of 2023
2023 · fourth_quarter · Firm: REGENXBIO
Proposals to change subject matter patent eligibility under Section 101 and other proposals to amend the patent code as they relate to gene therapies and other biopharmaceutical innovations, including: S.2140, the Patent Eligibility Restoration Act and the Coons/Tillis-Buck/Ross PREVAIL Act related to PTO PTAB reform. Assertions of March In Rights under the Bayh-Dole Act or under Section 1498 against biopharmaceutical products. Efforts to impose "reasonable pricing clauses" on patent licenses from NIH-grantees to commercial partners. The ongoing PTO-FDA collaboration on drug pricing.
Client expense: $91,000 · Firm income: —
Matched citations: S.2140
Proposals to allow the direct expensing of R&D expenditures, including S.866, the American Innovation and Jobs Act (S.866) and the Build It in America Act (H.R. 3938).
Client expense: $91,000 · Firm income: —
Matched citations: S.866
Issues affecting biotechnology firms engaged in developing gene therapies, including: the MVP Act (H.R.2666) authorizing value based payments under the Medicaid program; Proposals to amend the drug pricing provisions of the Inflation Reduction Act such as reducing the 13-year period before newly approved biologics are subject to negotiated prices; Changes to the Orphan Drug Act; and, Potential legislative or administrative changes to the FDA accelerated approval program including reimbursement of AAP-approved gene therapies (e.g., MedPAC recommendations to cap prices for FDA AAP-approved products under certain circumstances.) Efforts to enact a so-called "reasonable pricing clause" in NIH licenses and CRADAs
Client expense: $94,000 · Firm income: —
Matched citations: H.R.2666
Proposals to allow the direct expensing of R&D expenditures, including S.866, the American Innovation and Jobs Act (S.866) and the Build It in America Act (H.R. 3938).
Client expense: $94,000 · Firm income: —
Matched citations: H.R. 3938
Patent Eligibility Restoration Act of 2023
2023 · third_quarter · Firm: REGENXBIO
Proposals to change subject matter patent eligibility under Section 101 and other proposals to amend the patent code as they relate to gene therapies and other biopharmaceutical innovations, including: S.2140, the Patent Eligibility Restoration Act and the Coons/Tillis-Buck/Ross PREVAIL Act related to PTO PTAB reform. Assertions of March In Rights under the Bayh-Dole Act or under Section 1498 against biopharmaceutical products. Efforts to impose "reasonable pricing clauses" on patent licenses from NIH-grantees to commercial partners. The ongoing PTO-FDA collaboration on drug pricing.
Client expense: $94,000 · Firm income: —
Matched citations: S.2140
Proposals to allow the direct expensing of R&D expenditures, including S.866, the American Innovation and Jobs Act (S.866) and the Build It in America Act (H.R. 3938).
Client expense: $94,000 · Firm income: —
Matched citations: S.866
Medicaid VBPs for Patients Act
2023 · third_quarter · Firm: KNIGHT CAPITOL CONSULTANTS
Issues affecting biotechnology firms engaged in developing gene therapies, including: the MVP Act (H.R.2666) authorizing value based payments under the Medicaid program; Proposals to amend the drug pricing provisions of the Inflation Reduction Act such as reducing the 13-year period before newly approved biologics are subject to negotiated prices; Changes to the Orphan Drug Act; and, Potential legislative or administrative changes to the FDA accelerated approval program including reimbursement of AAP-approved gene therapies (e.g., MedPAC recommendations to cap prices for FDAcAAP-approved products under certain circumstances.) Potential amendments to the Food, Drug and Cosmetic Act, the Public Health Service Act, or the Social Security Act that would impact the provision of cell and gene therapies (no specific legislation):. -
Client expense: — · Firm income: $60,000
Matched citations: H.R.2666
Medicaid VBPs for Patients Act
2023 · third_quarter · Firm: KNIGHT CAPITOL CONSULTANTS
Potential amendments to the Social Security Act to allow value-based pricing under Medicaid (HR 2666)
Client expense: — · Firm income: $60,000
Matched citations: HR 2666
Medicaid VBPs for Patients Act
2023 · second_quarter · Firm: KNIGHT CAPITOL CONSULTANTS
Issues affecting biotechnology firms engaged in developing gene therapies, including: the MVP Act (H.R.2666) authorizing value based payments under the Medicaid program; Proposals to amend the drug pricing provisions of the Inflation Reduction Act such as reducing the 13-year period before newly approved biologics are subject to negotiated prices; Changes to the Orphan Drug Act; and, Potential legislative or administrative changes to the FDA accelerated approval program including reimbursement of AAP-approved gene therapies (e.g., MedPAC recommendations to cap prices for FDAcAAP-approved products under certain circumstances.) Potential amendments to the Food, Drug and Cosmetic Act, the Public Health Service Act, or the Social Security Act that would impact the provision of cell and gene therapies (no specific legislation):. -
Client expense: — · Firm income: $60,000
Matched citations: H.R.2666
Medicaid VBPs for Patients Act
2023 · second_quarter · Firm: KNIGHT CAPITOL CONSULTANTS
Potential amendments to the Social Security Act to allow value-based pricing under Medicaid (HR 2666)
Client expense: — · Firm income: $60,000
Matched citations: HR 2666
Issues affecting biotechnology firms engaged in developing gene therapies, including: the MVP Act (H.R.2666) authorizing value based payments under the Medicaid program; Proposals to amend the drug pricing provisions of the Inflation Reduction Act such as reducing the 13-year period before newly approved biologics are subject to negotiated prices; Changes to the Orphan Drug Act; and, Potential legislative or administrative changes to the FDA accelerated approval program including reimbursement of AAP-approved gene therapies (e.g., MedPAC recommendations to cap prices for FDAcAAP-approved products under certain circumstances.)
Client expense: $90,000 · Firm income: —
Matched citations: H.R.2666
Proposals to allow the direct expensing of R&D expenditures, including S.866, the American Innovation and Jobs Act (S.866) and the Build It in America Act (H.R. 3938).
Client expense: $90,000 · Firm income: —
Matched citations: H.R. 3938
Patent Eligibility Restoration Act of 2023
2023 · second_quarter · Firm: REGENXBIO
Proposals to change subject matter patent eligibility under Section 101 and other proposals to amend the patent code as they relate to gene therapies and other biopharmaceutical innovations, including: S.2140, the Patent Eligibility Restoration Act and the Coons/Tillis-Buck/Ross PREVAIL Act related to PTO PTAB reform. Assertions of March In Rights under the Bayh-Dole Act or under Section 1498 against biopharmaceutical products The ongoing PTO-FDA collaboration on drug pricing
Client expense: $90,000 · Firm income: —
Matched citations: S.2140
Proposals to allow the direct expensing of R&D expenditures, including S.866, the American Innovation and Jobs Act (S.866) and the Build It in America Act (H.R. 3938).
Client expense: $90,000 · Firm income: —
Matched citations: S.866
Potential amendments to the Food, Drug and Cosmetic Act, the Public Health Service Act, or the Social Security Act that would impact the provision of cell and gene therapies (no specific legislation):to any successor to the Guthrie-Schrader MVP Act (formerly HR 7389) authorizing Medicaid value-based payments; -Changes to the Orphan Drug Act; -legislation affecting reimbursement of pharmaceuticals, including potential amendments to the Inflation Reduction Act; -
Client expense: — · Firm income: $60,000
Matched citations: HR 7389
Issues related to biotechnology firms engaged in developing gene therapies, including: Successor legislation to the 117th Congress Guthrie-Schrader MVP Act (H.R. 7389) authorizing value based payments under the Medicaid program; Proposals to amend the drug pricing provisions of the Inflation Reduction Act such as reducing the 13-year period before newly approved biologics are subject to negotiated prices; Changes to the Orphan Drug Act; and, Amendments to the FDA accelerated approval program including reimbursement of AAP-approved gene therapies.
Client expense: $163,000 · Firm income: —
Matched citations: H.R. 7389
Proposals to allow the direct expensing on R&D expenditures, including the Hassan-Young bill, S.866, he American Innovation and Jobs Act.
Client expense: $163,000 · Firm income: —
Matched citations: S.866
Elijah E. Cummings Lower Drug Costs Now Act
2022 · fourth_quarter · Firm: KNIGHT CAPITOL CONSULTANTS
Inclusion of provisions affecting the reimbursement of gene therapies that may be contained in any drug pricing legislation or budget legislation (H.R. 3 or its successor; the Build Back Better Act (HR 5376)/or any successor reconciliation bill. Development of Value Based Purchasing legislation ( HR 7389). Consolidated Appropriations Act, 2023 (PL 117-328).
Client expense: — · Firm income: $60,000
Matched citations: H.R. 3
Newborn Screening Saves Lives Reauthorization Act of 2021
2022 · fourth_quarter · Firm: KNIGHT CAPITOL CONSULTANTS
Potential legislation implementing value based purchasing for pharmaceuticals (HR 7389); Possible provisions related to Drug Pricing Legislation that affect biological products' development, approval, accelerated approval, and marketing, including deliberations associated with the Reauthorization of the Prescription Drug User Fee Act ( HR 7667) (S 4348), or the continuing resolution(Further Extendjnf Government Funding Act P.L. 117-70. Possible drug pricing legislation included in any budget reconciliation legislation ( no specific number). Reauthorization of the Newborn Screening Saves Lives Act (HR 482, S 350.) Consolidated Appropriations Act, 2033. ( PL 117-328).
Client expense: — · Firm income: $60,000
Matched citations: HR 482
Inflation Reduction Act of 2022
2022 · fourth_quarter · Firm: KNIGHT CAPITOL CONSULTANTS
Potential changes in the corporate tax rate or other provisions of interest to business (Build Back Better Act, H.R. 5376 or any successor budget reconciliation legislation; Consolidated Appropriations Act, 2023, PL 117-328).
Client expense: — · Firm income: $60,000
Matched citations: H.R. 5376
Inflation Reduction Act of 2022
2022 · fourth_quarter · Firm: KNIGHT CAPITOL CONSULTANTS
Inclusion of provisions affecting the reimbursement of gene therapies that may be contained in any drug pricing legislation or budget legislation (H.R. 3 or its successor; the Build Back Better Act (HR 5376)/or any successor reconciliation bill. Development of Value Based Purchasing legislation ( HR 7389). Consolidated Appropriations Act, 2023 (PL 117-328).
Client expense: — · Firm income: $60,000
Matched citations: HR 5376
Source: Senate LDA